Bioactive Electrospun Scaffolds Delivering Growth Factors and Genes for Tissue Engineering Applications by Ji, Wei et al.
EXPERT REVIEW
Bioactive Electrospun Scaffolds Delivering Growth Factors
and Genes for Tissue Engineering Applications
Wei Ji & Yan Sun & Fang Yang & Jeroen J. J. P . van den Beucken & Mingwen Fan & Zhi Chen & John A. Jansen
Received: 30 August 2010 /Accepted: 3 November 2010 /Published online: 19 November 2010
# The Author(s) 2010. This article is published with open access at Springerlink.com
ABSTRACT A biomaterial scaffold is one of the key factors
for successful tissue engineering. In recent years, an increasing
tendency has been observed toward the combination of scaf-
folds and biomolecules, e.g. growth factors and therapeutic
genes, to achieve bioactive scaffolds, which not only provide
physical support but also express biological signals to modulate
tissue regeneration. Huge efforts have been made on the
exploration of strategies to prepare bioactive scaffolds. Within
the past five years, electrospun scaffolds have gained an
exponentially increasing popularity in this area because of their
ultrathin fiber diameter and large surface-volume ratio, which is
favored for biomolecule delivery. This paper reviews current
techniques that can be used to prepare bioactive electrospun
scaffolds, including physical adsorption, blend electrospinning,
coaxial electrospinning, and covalent immobilization. In addition,
this paper also analyzes the existing challenges (i.e., protein
instability, low gene transfection efficiency, and difficulties in
accurate kinetics prediction) to achieve biomolecule release
from electrospun scaffolds, which necessitate further research to
fully exploit the biomedical applications of these bioactive
scaffolds.
KEY WORDS electrospinning.genedelivery.protein
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ABBREVIATIONS
ALP alkaline phosphatase
BMP2 bone morphogenic protein
2 (protein form)
bmp2 bone morphogenic protein
2 (gene form)
BSA bovine serum albumin
EGF epidermal growth factor
FA folic acid
HA hyaluronic acid
HAp hydroxylapatite
NGF nerve growth factor
pBMP-2 plasmid DNA encoding bone
morphogenic protein-2
PCL poly(ε-caprolactone)
PCL-b-PEG poly(ε-caprolactone)-block-poly(ethylene
glycol)
pCMV-EGFP plasmid DNA encoding enhanced
green fluorescent protein with a
cytomegalovirus promoter
pCMVβ plasmid DNA encoding β-galactosidase
PDGF-bb platelet-derived growth factor-bb
PDLLA poly (D,L-lactide)
pDNA plasmid deoxyribonucleic acid
PEG-b-PDLLA poly (ethylene glycol)-block-poly(D,L-lactide)
pEGFP-N1 plasmid DNA encoding a red shifted
variant of wild-type green
fluorescent protein
pGL3 plasmid DNA encoding luciferase
PLCL poly(L-lactide-co-epsilon-caprolactone)
PLGA poly(lactide-co-glycolide)
PMMAAA copolymer of methyl methacrylate
(MMA) and acrylic acid (AA)
PSU polysulphone
PVA poly(vinyl alcohol)
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Tissue engineering is an interdisciplinary field that applies
the principles of engineering and life sciences toward the
development of functional substitutes for damaged tissues.
The fundamental concept behind tissue engineering is to
utilize the body’s natural biological response to tissue
damage in conjunction with engineering principles (1). To
achieve successful tissue regeneration, three key factors are
to be considered: cells, scaffolds, and biomolecules (e.g.,
growth factor, gene, etc.). Currently, two strategies have
emerged as the most promising tissue engineering ap-
proaches (Fig. 1)( 2). One is to implant pre-cultured cells
and synthetic scaffold complexes into the defect place. In
this approach, the seeded cells are generally isolated from
host target tissues, for which they provide the main resource
to form newly born tissue. The synthetic scaffolds, on the
other hand, provide porous three-dimensional structures to
accommodate the cells to form extracellular matrix (ECMs)
and regulate the cell growth in vivo (3,4). These synthetic
scaffolds are biodegradable and degrade in accordance with
the tissue regeneration time frame. The other approach is
to place acellular scaffolds immediately after injury. The
governing principle of this approach is using scaffolds to
deliver appropriate biomolecules to the defect area; the
biomolecules are released from the scaffolds in a controlled
manner and may recruit progenitor cells toward the defect
area and promote their proliferation and differentiation,
thereby enhancing tissue regeneration.
In recent years, an increasing trend toward the combi-
nation of these two approaches is observed (5–8), because
the scaffolds with controlled release of biomolecules can
induce the seeded cells to proliferate and differentiate
during an ex vivo pre-culture period, thereby encouraging
tissue formation after implantation in vivo. Meanwhile, the
scaffolds will continue to release signal molecules after
implantation to enhance the desired physiological response
and, consequently, enhance tissue regeneration in the defect
area. In view of these strategies, to achieve successful and
efficient tissue engineering, an increasing demand exists for
bioactive scaffolds that can provide more than only physical
support for cells but also a local release of bimolecules to
influence surrounding tissue regeneration. This type of
scaffold is termed “bioactive scaffold” (1).
The importance of bioactive scaffolds in tissue engineer-
ing has been comprehensively reviewed (9). Various
biomolecules can be incorporated within tissue-engineered
scaffolds to enhance their functional properties for biomed-
ical applications. The most frequently used biomolecules
are proteins (e.g., growth factors or cytokines) and growth
factor coding genes. Growth factors (GFs) are endogenous
proteins capable of binding cell-surface receptors and
directing cellular activities involved in the regeneration of
new tissue (10). Localized delivery of exogenous GFs is
suggested to be therapeutically effective for production of
cellular components involved in tissue development and the
healing process, thus making them important factors for
tissue regeneration (11). Nevertheless, it has to be empha-
Fig. 1 Current tissue engineering approaches. a To implant pre-cultured cells-scaffolds complex into the defect place, cells are isolated from biopsy and
then cultured in vitro for expansion. Then the cells are seeded onto synthetic scaffolds, which provide a porous three-dimensional structure to
accommodate seeding cells to form extracellular matrix; b to place acellular scaffolds with biomolecules delivery immediately after injury, the biomolecules
are released from scaffolds in a controlled manner, and they may recruit the progenitor cells in wound area and promote their proliferation and
differentiation.
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scaffolds depends on the large-scale production of recom-
binant GFs, which is quite expensive. Additionally, protein
bioactivity after incorporation within scaffolds also needs to
be considered in view of efficacy issues. Instead of growth
factor delivery, gene therapy presents a new paradigm in
tissue engineering. This concept gives birth to gene-activated
scaffolds (GASs), which are defined as scaffolds incorporating
therapeutic protein-encoding genes (12). GASs ensure the
delivery of genes at the desired site (13), after which
transfection into target cells is required to produce thera-
peutic proteins (14). Compared to growth factor delivery,
gene delivery is advantageous in its long-term effect as well
as relatively low cost, which makes it promising for tissue
engineering application.
Since the last decade, huge efforts have been made to
explore strategies for the preparation of bioactive scaffolds
to deliver therapeutic proteins or genes, and a series of
comprehensive reviews has provided detailed information
for these strategies (14–16). In general, proteins or genes
can be delivered by micro/nano-particles (17), hydrogels
(18) or electrospun fibrous matrices (19,20). For micro/
nano-particles, due to their fluidity, it is difficult to keep
them localized in the defected area to give new tissues
enough support (21). Therefore, such particles can only be
used as carriers for biomolecules rather than scaffolds for
tissue engineering. Comparably, hydrogels have been used
as drug delivery systems for many years, but the poor
mechanical properties of hydrogel-based scaffolds limits
their use for load-bearing applications, and this disadvan-
t a g ec a ne v e nr e s u l ti nt h ep r e m a t u r ed i s s o l u t i o no r
displacement of the hydrogel from a targeted local site
(22). Electrospinning is a popular technique to prepare
tissue engineering scaffolds due to its relative simplicity
regarding the generation of fibrous scaffolds with nano- or
submicron-scale dimensions, which morphologically resem-
ble the natural ECM. Due to the possibility of ultrathin
fiber diameters, electrospun fibrous matrices can have a
large specific surface area, which enables effective delivery
of biomolecules. Furthermore, the loose bonding between
fibers is beneficial for tissue growth and cell migration
(23). These characteristics endue electrospinning with
superiority in preparation of bioactive scaffolds. In 2003,
electrospinning was first used to prepare bioactive scaffolds
with gene release (24), and, thereafter, this technique has
gained exponentially increasing popularity in this area
(Fig. 2). The aim of this paper is to review the techniques
to incorporate growth factors or genes into electrospun
scaffolds. Additionally, the existing challenges of using
electrospinning in the area of tissue regeneration will be
discussed.
BASICS RELEVANT TO ELECTROSPINNING
Electrospinning is a cost-efficient technique to prepare ultra-
fine polymeric fibers, which can be easily employed in the
laboratory and scaled up to an industrial process. It utilizes
electrostatic forces to spin polymer solutions or melts into
whipped jets, resulting in continuous fibers with diameters
from a few nanometers to micrometers after solvent
evaporation in the spinning process (25,26). A typical
electrospinning apparatus consists of four major compo-
nents: (1) a syringe pump, which controls the feeding rate of
polymer solution to be electrospun; (2) a needle, through
which the solution goes into a high electric field; (3) a high
voltage source, which stretches the polymer solution into
ultrathin fibers; and (4) a grounded fiber collector, where
electrospun fibers can be collected in a static or dynamic
way (Fig. 3).
Fig. 2 Publications and citations
report from ISI web of Science®,
as of August 18, 2010.
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sively reviewed (25,27): when high voltage is applied, the
polymer solution droplet from the needle becomes highly
electrified and tends to form a conical shape known as the
Taylor cone, depending on the surface tension of the liquid
and the force of electric field; once the electric field
surpasses a threshold, the electric force overcomes the
surface tension and viscoelastic force of the polymer
droplet, which results in a finely charged jet from the tip
of the Taylor cone; then, the jet sprays into one continuous
ultrathin fiber. The random or aligned fibers can be
collected on a grounded metallic collector in the form of
a plate, cylinder or disc type (27). Based on this theory, it is
clear that the electrospinning process can be manipulated
by a number of variables. These variables include solution
properties (polymer concentration, polymer moleculer
weight), system set-up (applied voltage, feeding rate and
collecting distance), and environmental factors (temperature
and humidity) (20,25). Among these variables, solution
properties are crucial for a succesful electrospinning.
Further, literature indicates that low polymer weight, high
fluidity or high density of the polymer solution will cause
instabilities, including whipping and droplet instead of
uniform fiber formation (28). In addition, sub-optimal
voltage is another key factor that could lead to bead-like
defects in the spun fibers or even failure in jet formation
(20,25).
There is a wide range of material choices to prepare
electrospun scaffolds for tissue engineering applications,
which mainly includes two categories: natural polymers and
synthetic polymers. In principle, the material choice for
scaffold preparation depends on the purpose of application
and feasibility of electrospinning. Electrospun fibrous
scaffolds prepared from natural polymers, especially colla-
gen, are mostly used because these can mimic the
properties of natural ECM for engineered tissues (29).
However, some natural polymers are not easy to handle
during electrospinning, as they tend to display poor
processibility, which needs to be modified to achieve better
electrospinning (30). Furthermore, it is difficult to confirm
that native structure and biological characteristics of
natural polymers are still preserved after electrospinning
(31). In contrast, synthetic polymers (especially the
polyesters) are much easier to be optimized for electro-
spinning process and, hence, are more commonly applied.
Dong et al.( 32) gave a comprehensive review listing different
synthetic polymers that can be used to prepare electrospun
scaffolds. Among multiple choices of synthetic polymers, poly
(ε-caprolactone) (PCL), poly(lactic acid) (PLA), poly(glycolic
acid) (PGA) and their copolymers poly(lactic-co-glycolic acid)
(PLGA) are most extensively used for biomedical applications
because they are approved by the US Food and Drug
Association (FDA) for their good biocompatibility as well as
biodegradability.
CURRENT PROGRESS OF ELECTROSPUN
SCAFFOLDS WITH BIOMOLECULE DELIVERY
General Considerations for Growth Factor and Gene
Delivery
There are two important aspects to achieve a successful
delivery: (1) to ensure the bioactivity of the biomolecules
incorporated within the scaffolds and (2)tofitthe release profile
of biomolecules within the time-frame of tissue regeneration.
Principles for Growth Factor Delivery
Growth factors easily lose their activity upon chemical or
physical processing. Therefore, the preservation of protein
activity is a prerequisite for succucessful growth factor
delivery. There are three stages during which the stability
of a growth factor incorporated in a scaffold must be
preserved: (1) scaffold fabrication, (2) scaffold storage, and
(3) scaffold degradation. The source of the protein stability
in each stage and available strategies to improve the protein
stability will be explained in detail in “Protein Instability.”
The release profile is another important issue to take
into account when designing electrospun scaffolds to deliver
growth factors. Considering that the half-lives of most
growth factors in serum are very short, it is essential for
bioactive scaffolds to maintain a desired temperospatial
growth factor concentration to direct tissue regeneration.
For this purpose, an optimal growth factor-delivering
scaffold should be able to initially release part of the dosage
contained, which is typically termed “burst release” (33), to
rapidly get the effective therapeutic concentration. Subse-
quently, well-defined release kinetics follow in order to
provide the maintenance dosage enabling the attainment of
the desired concentration (34).
Fig. 3 Scheme for electrospinning apparatus.
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Different from growth factors, which act extracellularly and
initiate a biological response by binding to cell surface
receptors, target genes will only have an intracellular effect
by integrating into the host genome of endogenous cells and
transforming the transfected cells into local bio-activated
actors to enhance tissue formation. Consequently, a
prerequisite for a successful gene delivery scaffold is that
the active gene can be released from the scaffold, after
which it needs to be integrated into the host genome. To
achieve this goal, the target gene is always packed within
vectors before it is incorporated into the scaffolds, because
vectors can protect the target genes from extracellular
DNA-degrading enzymes and intracellular lysosomes that
contain digestive enzymes in the process of target gene
being taken up by surrounding cells (13). On the other
hand, vectors can transport genes through the lipid bilayer
of the cell membrane, and the latter is the biggest obstacle
in gene transfection. Currently, two categories of vectors
are used: viral and non-viral vectors. The strategies of
effective vectors have been clearly reviewed by Storrie et al.
and Kootstra et al.( 14,35).
Similar to growth factor delivery, an important issue for
gene delivery is to modulate both the concentration and
duration of the gene particles released from scaffolds, which
dictates a well-controlled release profile. To achieve
successful gene transfection, the effective concentration of
target gene-vector complexes should be released into the
cell-surrounding microenvironment within an optimal time-
frame. It is found that a low concentration of DNA always
results in low transfection efficiency (36,37), and much too
fast gene release leads to a low transfection efficiency,
because superabundant gene complexes may lose activity if
transfection is not achieved in due time (37).
Fabrication Techniques for Electrospun Scaffolds
with Biomolecule Delivery Capacity
In general, biomolecules can be delivered either directly
from the electrospun scaffolds or from additional separate
release system (i.e., micro/nanospheres) loaded into the
scaffolds, where the electrospun scaffolds behave only as a
supporting structure. Since using micro/nano-spheres to
deliver biomolecules has been comprehensively reviewed
(38–41), this topic will not be addressed in this review.
Different proteins and genes that have been loaded in
electrospunscaffoldsare listed inTablesI and II, respectively.
Physical Adsorption
The easiest way to load biomolecules into electrospun
scaffolds is to dip the scaffolds into an aqueous phase
containing biomolecules (Fig. 4a). In this approach,
biomolecules can be in the form of pure solution or
emulsions, and they can attach to the scaffolds via
electrostatic forces. Although this approach gives little
interference with the activity of loaded biomolecules, it is
seldom used to load protein or genes in electrospun
scaffolds due to the uncontrolled release profiles. It has
been shown that bone morphogenic protein-2 (BMP2)
adsorbed to PLGA scaffolds reached over 75% release
within 5 days and nearly complete release within 20 days
This release rate was much faster than that of the same
amount of protein loaded in PLGA scaffolds using blend
electrospinning (21). Similar evidence is available for gene
delivery using this approach. Although some researchers
could obtain transfected cells in an early stage (most likely
due to a large amount of target gene bulk release (36,37)),
the released gene exhausted within a short time, and over
95% of incorporated DNA released within 10 days (37).
Blend Electrospinning
In blend electrospinning, biomolecules are mixed within the
polymer solution, after which the mixed solution is used in
the electrospinning process to fabricate a hybrid scaffold
(Fig. 4b). Some researchers emphasized the preparing
process of suspending the protein solution in polymer
solution by emulsifying using ultra-sonication or homoge-
nizer, therefore naming the process “emulsion electro-
spinning” (42). The idea for emulsification arises from the
improvement of biomolecule suspension in organic solvents.
Considering its same principle, we assume that it still
belongs to blend electrospinning approach.
As blend electrospinning localizes biomolecules within
the fibers of the scaffolds rather than simply adsorb them
superficially to the scaffolds, it is assumed that this
approach allows more sustained release profiles compared
to physical adsorption. Researchers have used blend
electrospinning to incorporate various types of proteins
and genes in scaffolds, including bovine serum albumin
(BSA) (43–45), lysozyme (42,46) and growth factors (e.g.,
BMP2 (21,47), epidermal growth factor (EGF) (48). In
general, a sustained release profile can be obtained over
several weeks using this technique.
Although blend electrospinning is assumed to be
relatively easy to perform, an inconvenient issue is the
activity loss of incorporated biomolecules. This is especially
vital for proteins, because they may lose their bioactivity
due to conformational changes in the organic solution
environment. On the other hand, the process to prepare
protein emulsions, which involves mechanical stirring,
homogenization or ultrasonication, can also damage pro-
tein function (49). In previous studies, several strategies
have been applied to improve protein stability. A strategy is
Bioactive Electrospun Scaffolds 1263to use salt complexation instead of emulsification to
improve protein solubility in organic solvents. Li et al.( 46)
incorporated lysozyme-oleate complex into electrospun
membranes, and their results showed that the released
lysozyme retained over 90% of bioactivity. Another strategy
is to use hydrophilic additives to minimize the hydrophobic
interaction of protein and organic solvents during electro-
spinning (50–52). It has been reported that hydrophilic
polymers, such as poly(ethylene glycol) (PEG) and poly
(ethylene oxide) (PEO) added in the aqueous protein
Table I Proteins that Have Been Loaded into Electrospun Scaffolds
Fabrication technique Loaded Protein Scaffold material Biological application Reference
Physical adsorption BMP2 PLGA BMP2 release in vitro & human bone marrow stem cell culture (21)
BMP2 PLGA Implantation of tibia defect in nude mice (54)
Blend electrospinning BSA PEO – (43)
BSA PVA BSA release in vitro (44)
BSA PDLLA BSA release in vitro & structural integrity analysis (45)
lysozyme PDLLA Lysozyme release in vitro, structural integrity & enzymatic analysis (42)
lysozyme PCL Lysozyme release in vitro & enzymatic analysis (46)
bFGF PLGA bFGF release in vitro & rat bone marrow cell culture
to test bioactivity of released bFGF
(67)
EGF Silk fibroin EGF release in vitro & human dermal fibroblasts culture (48)
BMP2 Silk fibroin Human bone marrow stem cell culture (47)
BMP2 PLGA BMP2 release in vitro & human bone marrow stem cell culture (21)
Coaxial electrospinning BSA PCL BSA release in vitro (61,62,64,68)
BSA PLCL BSA release in vitro (63)
lysozyme PCL Enzymatic analysis of released lysozyme (62)
PDGF-bb PCL NIH3T3 cell culture to test bioactivity of released PDGF-bb (64)
PDGF-bb PLCL PDGF-bb release in vitro & vascular smooth muscle
cells to test bioactivity of released PDGF-bb
(65)
NGF PLCL Rat pheochromocytoma cell line culture
to test bioactivity of released NGF
(66)
bFGF PLGA bFGF release in vitro & rat bone marrow cell culture
to test bioactivity of released bFGF
(67)
ALP – Enzymatic analysis of the post-electrospun ALP (68)
Covalent immobilization BSA PEG-b-PDLLA In vitro culture of human dermal fibroblast (89)
BSA PCL/PCL-b-PEG mixture In vitro culture of NIH3T3 cells (73)
EGF PCL/PCL-b-PEG mixture In vitro culture of human primary keratinocytes (74)
bovine collagen I PMMAAA In vitro culture of cortical neural stem cells (72)
BSA PSU – (75)
Table II Genes that Have Been Loaded into Electrospun Scaffolds
Fabrication technique Loaded gene particles Scaffold material Application Reference
Physical adsorption pGL3 PLA Deliver gene into COS-7 cell line in vitro (90)
pBMP-2 PLGA/HAp Deliver gene into hMSC in vitro & bone regeneration in nude mice (36,37)
Blend electrospinning pBMP-2 PLGA/HAp Deliver gene into hMSC in vitro & bone regeneration in nude mice (36,37)
pBMP-2 Silk/PEO/nHAp Deliver gene into hMSCs in vitro for bone tissue engineering (47)
Adenovirus E1 Chitosan/PEG/FA Deliver gene into HEK293 cell line for cancer therapy (91)
pCMVβ PLA-PEG/PLGA In vitro gene delivery into MC3T3-E1 cell line (24,57)
Coaxial electrospinning pCMV-EGFP PEI-HA/PCL Non-viral gene delivery into CRL1764 cell line in vitro (69)
Adenovirus E1/E3 PCL/PEG Viral gene delivery into HEK293 cell line in vitro (70)
Covalent immobilization LPEI-pEGFP-N1 PCL-PEG Deliver gene into NIH3T3 cell line in vitro & animal (71)
study in vivo for local gene therapy of diabetic ulcers
1264 Ji et al.Fig. 4 Fabricationtechniques of bioactiveelectrospunscaffolds.a physical adsorption; b blend electrospinning; c coaxial electrospinning; d covalent immobilization.
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stability. Futhermore, a recent study showed that hydroxy-
apatite (HAp) particles were able to preserve the activity of
BMP2 loaded in electrospun PLGA scaffolds, as proteins
can attach to these hydrophilic particles so as to escape the
harsh electrospinning process (21).
A typical protein release profile from blend electrospun
scaffolds is an initial burst release followed by a sustained
release close to a linear mode (24,44,46,54,55). The burst
release usually occurs within 24 h, regardless of polymer
type for scaffolds preparation. This initial burst release may
be related to the migration of protein during drying and
storage steps, which localizes a certain fraction of protein
molecules near the fiber surface (56). The high solubility
and partition coefficients of the incorporated protein can
lead to a rapid release through short diffusion pathways due
to thermodynamic imbalances (33). After burst release, the
protein release behavior is mainly driven by protein
diffusion or the effect of polymer degradation and protein
diffusion. For slowly degradable polymers, such as PCL, the
protein release profile behaves as a relatively linear mode
(56), whereas for PLGA, a polymer with relatively short
degradation time, the protein release profile shows a
sustained mode followed by an obvious increased release
rate once the polymer starts to degrade (21,54). The
protein release profile can be modulated by additives
loaded together with protein during blend electrospin-
ning. The addition of hydrophilic additives, such as
hydroxyapatite particles (21,54)a n dP E G( 46), will
improve the hydrophility of scaffolds and, hence, enhance
water uptake of the scaffolds as well as accelerate protein
release from electrospun scaffolds.
The first gene delivery using blend electrospinning
approach was reported by Luu et al.( 24). In this study,
the authors mixed pCMVβ plasmid (7,164 bp) encoding b-
galactosuchsidase with PLA–PEG–PLA tri-block copolymer
andhighmolecularweight(75kDa)PLGA(LA/GA=75/25).
Since then, many groups have used this approach to
incorporate bmp2 with different plasmids into electrospun
scaffolds (37,47). In this approach, the plasmid gene is able
to withstand the electrospinning process because of the
protection from complexation with vectors. Luu et al.( 24)
found that DNA kept its structural integrity after release out
of PLGA scaffolds. Nie et al.( 36) also showed that the
incorporated bmp2 was still capable of inducing BMP2
expression in vivo after 4 weeks.
Different from protein release, gene release shows two
types of profiles from blend electrospun scaffolds, which
might be related to different fiber compositions. Luu et al.
(24) reported a burst release within 2 h followed by a
sustained DNA release until 20 days using PLA–PEG block
copolymers blended with different variations of PLGA,
whereas others obtained a linear release profile up to
2 months from composite PLGA electrospun scaffolds
(37,57).
Coaxial Electrospinning
Coaxial electrospinning, also known as co-electrospinning,
was first demonstrated by Sun et al.( 58). In coaxial
electrospinning, two solutions (i.e. polymer solution and
biological solution) are coaxially and simultaneously elec-
trospun through different feeding capillary channels in one
needle to generate composite nano-fibers with core-shell
structures (Fig. 4c). Coaxial electrospinning is a very
dynamic process, and many factors, such as feeding rate
of the inner and outer fluids, interfacial tension and visco-
elasticity of the two solutions, affect the entrapment of
components in the core part (58,59). Although this
technique was developed more than 10 years ago (60), the
application of coaxial electrospinning to deliver biomole-
cules has only been explored since 5 years ago (24,44) due
to the complexity of this technique.
Recently, coaxial electrospinning has gained increased
popularity in the protein delivery field because the
produced core-shell fibers have great potential in preserving
proteins during the electrospinning process. In addition, it
provides homogeneous protein distribution throughout the
fibers, and proteins can be delivered in a controlled manner
due to the shell barrier (Fig. 5). Researchers have achieved
encapsulation of different types of proteins in coaxially
electrospun scaffolds, including BSA (56,61–63), lysozyme
(62), platelet-derived growth factor-bb (PDGF-bb) (64,65),
nerve growth factor (NGF) (66) and fibroblast growth factor
(FGF) (67). These studies indicated that released growth
factors had efficient bioactivity to stimulate corresponding
cell growth. Some authors attribute this bioactivity preser-
vation only to the superiority of coaxial electrospinning, as
during coaxial electrospinning, the electric charges are
located predominantly at the outer fiber surface so that the
inner protein solutions are not charged at all (25). In
contrast, we compared the effect of blend and coaxial
electrospinning on protein activity by using alkaline
phosphatase (ALP) as a model protein, and our results
indicated that both electrospinning techniques depressed
the biological activity of the incorporated ALP, suggest-
ing that high voltage and contact with organic solvents
are harmful to the loaded biomolecules; the ALP
through coaxial electrospinning without PEG loaded
maintained significantly lower enzyme activity than the
one with PEG loaded regardless of electrospinning
method (68).
The protein release profile from coaxial electrospun
fibers also includes an initial burst release followed by a
sustained release stage (56,61,62,66,67), which is similar to
the one from blend electrospun scaffolds. However,
1266 Ji et al.compared to blend electrospinning, the burst release from
coaxial fibers is significantly lower, and the entire release
p r o f i l ei sm o r es u s t a i n e d( 56,68), because core-shell-
structured fibers provide a protein reservoir system with a
barrier membrane that controls the protein diffusion rate
(68).
To date, only a limited number of studies on gene
delivery via coaxial electrospinning scaffolds has been
published. Saraf et al.( 69) incorporated pDNA into an
aqueous poly(ethylene glycol) (PEG) solution to fabricate
the core of fibers and loaded hyaluronic acid (HA)
derivative of poly(ethylenimine) (PEI) as gene delivery
vector into an organic sheath polymer solution of poly
(ε-caprolactone) (PCL) to form the shell part. Their
results suggested that the plasmid diffusing out of the
fiber cores could complex with the positively charged
vector PEI-HA released from the fiber shells. In
addition, the released gene-vector complex could sus-
tainably transfect cells present on the scaffolds over
60 days with 15% transfection efficiency on average.
The authors concluded that transfection efficiency was
related to the concentration and molecular weight of the
core polymer PEG. However, the pDNA release was not
directly measured in their study. Liao et al.( 70)u s e d
core-shell fibers to deliver the adenovirus (Ad) encoding
gene of green fluorescence protein (GFP) in vitro.T h e y
succeeded to detect cells expressing GFP for more than
30 days, and the cell transfection efficiency could reach over
80%. However, the high transfection efficiency only sustained
for 2 weeks, which is related to the initial burst release. Their
results showed that different polymer compositions have
different pore formation ability on the fiber surface, which
contributed to different release profiles and cell transfection
efficiencies.
Covalent Immobilization
Covalent immobilization immobilizes biomolecules onto
the fiber surface via chemical bond, for instance, forming
peptide bond through amino groups (71) (Fig. 4d). Com-
pared to the above-mentioned strategies, this approach is
predominantly used to improve the surface properties of
electrospun fibers (72), but some researchers are applying
this approach to deliver protein aiming to achieve con-
trolled release profiles, because the release rate of the
immobilized biomolecules can be controlled by the external
enzymes.
Choi et al.( 73) reported that BSA-immobilized nano-
fibers showed no obvious burst release, although the
authors only observed the release within 1 week. Using
the same strategy, they prepared electrospun scaffolds with
epidermal growth factor (EGF) delivery and succeeded in
effective application of these bioactive scaffolds in vivo (74).
Kim et al.( 71) introduced a matrix metalloproteinases
(MMPs)-cleavable linker between gene-vector complex and
the electrospun scaffolds, so that gene release can be
controlled by external MMPs cleavage. Their results
showed that a fast gene release can be achieved in presence
of MMP-responsive peptides, for which the maximum
released amount was 82% within 12 h, whereas less than
40% of incorporated gene was released if MMPs were
absent.
So far, covalent immobilization is not a routine way to
deliver protein or genes from electrospun scaffolds due to its
technical complexity. In addition, some researchers also
doubt the uniformity loss of the scaffolds during surface
modification process (75), which might affect mechanical
properties of the scaffolds. In addition, the manipulation of
protein configuration and function by choosing specific
Fig. 5 Protein distribution and
core-shell structure of coaxial
electrospun fibers. a Laser
scanning confocal microscopy
images to visualize protein
distribution in coaxial electrospun
fibers. The panels in each image
are as follows: upper left: fitc-
labeled protein (green); upper
right: rhodamin B-labeled polymer
(red); bottom left: natural light;
bottom right: the merger of fitc
and rhodamin B. b Transmission
electron microscopy image to
visualize the core-shell structure of
the same coaxial electrospun
fibers. Arrows indicate the core
and shell parts within the fiber.
Bioactive Electrospun Scaffolds 1267binding sites in the protein molecule is still a big challenge.
However, surface covalent immobilization represents an
option to achieve delivery of multiple biomolecules in
combination with the biomolecules directly incorporated
within the scaffolds (11).
CHALLENGES AND OUTLOOK
Although electrospinning shows huge potential and prom-
ising application possibilities to prepare tissue engineering
scaffolds with biomolecule delivery, challenges still exist for
further application of such bioactive scaffolds, which
includes concerns about (1) protein instability, (2) low gene
transfection efficiency, and (3) difficulties in release kinetics
control.
Protein Instability
Maintaining protein conformation within the scaffolds will
be essential for further biomedical application of protein
delivery from electrospun scaffolds, because the loss of
conformation of a protein might not only be detrimental to
the bioactivity and hence therapeutic potential, but also
causes immunogenic effects related to exposure of non-
native peptide epitopes (76). Although it has been reported
that protein released from freshly prepared electrospun
scaffolds was capable of inducing various cellular responses
(21,42,45,54,65), indicating the preservation of protein
activity after the electrospinning process, it is too easy to
claim that proteins incorporated within electrospun scaf-
folds will behave similar to the virgin proteins. As
aforementioned, the threat for protein instability regarding
electrospun scaffolds might arise from either fabrication,
storage or degradation period. Also, it needs to be
mentioned that the instability of protein during storage
and degradation period is a general problem for polymeric
protein delivery system. Therefore, the development of
methods to optimize protein stability during these three
stages is a major challenge for effective protein delivery
from electrospun scaffolds.
During the scaffold preparation process, high voltage
and contact with organic solvents may be harmful to the
growth factor activity (42,53,77). Although using coaxial
electrospinning and adding hydrophilic additives (e.g.,
PEG, hydroxyapatite) was reported to minimize the
interaction between protein and organic phase (21,42), the
protein still loses 20% bioactivity due to the loss of α-helix
in secondary structure compared with virgin protein
solution (68).
Once the scaffolds are prepared, normally they are
lyophilized for storage before application. It has been
recognized that protein stresses may also arise from the
drying process without appropriate stabilizing excipients
(78). As a result, it is wise to include protein stabilizer within
the electrospun scaffolds to avoid the protein degradation
during lyophilization. The commonly used lyoprotectants
include sugars (e.g., sucrose) and polymers with relative
high collapse temperature (e.g., dextran) (78). Some authors
used PEG (56) or dextran (61) as protein stabilizer during
coaxial electrospinning, but they rarely mentioned the effect
of these additives on protein stability during lyophilization.
Sucrose is suggested to be effective at inhibiting unfolding
during lyophilization (78), but its effect on electrospun
scaffold fabrication and protein stabilization still needs further
investigation.
When the synthetic polymeric electrospun scaffolds start
to degrade, the acidic microenvironment induced by
hydrolysis products of polyesters is also likely to be
destructive to growth factor integrity (79,80). This is
especially a serious concern for PLGA, which is attractive
for biomolecule delivery because of its tailored degradation
rate to achieve controlled release. The instability of
incorporated proteins comes from deamidation at aspara-
gine residues, peptide bond hydrolysis and acylation of
protein primary amines (e.g., N-terminus, Lysine group) in
degrading PLGA systems. All these instabilities are related
to the acidic microclimate pH produced by the accumula-
tion of acidic monomers and oligomers during PLGA
degradation (80). In consequence, it is necessary to
maintain the pH during scaffold degradation to stabilize
the protein incorporated within PLGA delivering systems.
Currently, there are two effective approaches to maintain
pH within a PLGA protein delivery system. One is using
hydrophilic polymer PEG as porogen in PLGA scaffolds to
enhance acidic degraded products release (81), but this
approach will decrease the mechanical properties of electro-
spun scaffolds, which might limit its further application. The
other approach is adding poorly water-soluble basic salts such
as Mg(OH)2 to neutralize acidic microenvironment during
scaffolds degradation (82). However, it is interesting that the
use of this approach is not widespread in spite of its apparent
simplicity.
Low Gene Transfection Efficiency
Although many studies showed that it is feasible to deliver
target genes at the desired tissue site via electrospun scaffold
implantation (24,36,47,71), the low gene transfection
efficiency remains a drawback. Basically, the low efficiency
is not only an obstacle for electrospun scaffolds with gene
release, but also a key technical barrier for full exploitation
of the potential of gene therapies. In order to improve gene
transfection efficiency, viral vectors seem to be a straight-
forward option, as viral vectors have natural tropism for
living cells. However, their immunogenic potential and the
1268 Ji et al.threat of disturbing normal gene function from retroviruses
and adeno-associated viruses limits their further clinical
application (83,84). In recent years, other options for
improving transfection efficiency have been experimented
with, including nano-scaled delivery carriers (85), gene gun
(86), disulfide linkages in cationic polymers (87) and biores-
ponsive polymers (68). Unfortunately, those methods are
difficult to combine with electrospun scaffolds.
The poor interactions between released gene particles
and cells is another possible reason for the low gene transfer
efficiency via electrospun scaffolds. It is known that the
released gene dose has to reach a threshold to induce gene
transfection in cells, as recent studies have demonstrated
that low concentrations of released gene always yield a low
transfection efficiency (36,37).
Release Kinetics Control
In order to achieve an effective dose and a target release
profile, it is necessary to use mathematical models to predict
release kinetics on the basis of good estimates of the
required composition, geometry, and dimensions of the
biomolecular delivery system. A mechano-realistic mathe-
matical model is based on equations that describe real
phenomena, e.g. mass transport by diffusion, dissolution of
biomolecules, and/or the transition of a polymer from a
glassy to rubbery state (88). The mathematical modeling of
biomolecule delivery from polymeric matrices has been
clearly reviewed (34,88). Among different models, a simple
and useful empirical equation is the so-called power law
equation (34):
Mt=M1 ¼ ktn;
where M∞ is the amount of drug released after an infinite
time, k is a constant related to the structure and geometric
characteristics of the system, and n is the release exponent
indicating the mechanism of protein release (88). However,
it needs to be mentioned that, in practice, the release kinetics
are likely affected by many factors, including polymer
swelling, polymer erosion, biomolecular dissolution/diffusion
characteristics, biomolecules distribution inside the matrix,
biomolecule/polymer ratio and system (34). Apparently, it is
impossible for a single mathematic model to consider all
variables. Therefore, deviation will always exist between
theoretical prediction and practical realization. Furthermore,
in vivo biomolecule delivery from degradable polymeric
scaffolds will be strongly affected by the surrounding tissue
environment (e.g. pH value and cellular tissue reaction).
Nevertheless, there is no mathematical model available that
estimates biomolecule release from biodegradable vehicles
under physiological conditions. Consequently, it is necessary
to design advanced mathematical models considering in vivo
conditions.
SUMMARY
Tissue engineering is a promising research area for present
and future regenerative medicine, and the fundamental
concept behind tissue engineering is to utilize the body’s
natural biological response to tissue damage in conjunction
with engineering principles (1). In order to achieve
successful and efficient tissue engineering applications, there
is an increasing demand for bioactive scaffolds that can
provide more than only physical support for cells but also
local release of biomolecules to direct tissue regeneration in
the defect area. Growth factors and growth factor-coding
genes are the most straightforward biological stimuli to
promote tissue regeneration. Consequently, studies related
to the controlled delivery of growth factors and genes from
bioactive scaffolds show an exponential increase over the
last decade. Bioactive scaffolds with growth factor or gene
delivery can be prepared in the form of micro/nano-
spheres, hydrogel, as well as electrospun fibers. In recent
years, electrospun fibrous scaffolds have attracted in-
creasing attention due to the relative simplicity regarding
the generation of fibrous scaffolds with nanoscale
dimensions.
Electrospinning utilizes electrostatic forces to spin poly-
mer solutions or melts into whipped jets, revealing
continuous fibers with diameters from a few nanometers
to micrometers after solvent evaporation in the spinning
process. Because of the ultrathin fiber diameter, electrospun
scaffolds are considered as an effective delivery system for
biomolecules due to the stereological porous structure and
high specific surface area. Biomolecules can be incorporated
within electrospun scaffolds by physical adsorption, blend
electrospinning, coaxial electrospinning as well as covalent
immobilization after scaffolds fabrication. Although there has
been a substantial number of studies dedicated to the
methodology of preparing electrospun scaffolds to achieve
biomolecules delivery, further studies are needed to improve
the stability of incorporated protein, gene transfection
efficiency as well as the accuracy of release kinetics control.
Until now, only a limited number of research efforts
have focused on in vivo applications of electrospun scaffolds
with protein or gene delivery. Consequently, more animal
studies are needed to fully explore the potential of these
bioactive scaffolds for clinical applications. Close coopera-
tion between laboratory and clinics might eventually help to
translate this promising technique from bench to bed, and
it is likely that biomolecule delivery from electrospun
scaffolds will provide therapeutic benefit in regenerative
medicine in the near future.
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